non-deletion 5q
Showing 1 - 25 of >10,000
People Who Have Genetic Changes and Features of Autism: Simons
Recruiting
- 16P11.2 Deletion Syndrome
- +184 more
-
New York, New York
- +1 more
Jan 6, 2023
REVLIMID® Treatment of IPSS Low- or Intermediate-1-risk
Recruiting
- Myelodysplastic Syndromes
- +2 more
-
Anyang, Korea, Republic of
- +12 more
Apr 6, 2021
Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7) Trial in United
Completed
- Adult Acute Basophilic Leukemia
- +16 more
-
Little Rock, Arkansas
- +53 more
Jan 13, 2022
22q11.2 Deletion Syndrome Trial in Philadelphia (NFC-1)
Completed
- 22q11.2 Deletion Syndrome
-
Philadelphia, PennsylvaniaChildren's Hospital of Philadelphia
Mar 24, 2022
Neurodevelopmental Disorders, Autism, Autism Spectrum Disorder Trial in Canada (Sertraline, Placebo)
Not yet recruiting
- Neurodevelopmental Disorders
- +25 more
- Sertraline
- Placebo
-
Calgary, Alberta, Canada
- +6 more
Oct 11, 2023
Myelodysplastic Syndrome Trial in New York (Revlimid (Lenalidomide))
Active, not recruiting
- Myelodysplastic Syndrome
- Revlimid (Lenalidomide)
-
New York, New YorkColumbia University Medical Center
Jan 12, 2022
Glioma (Diagnosis), Liquid Biopsy, Deep Learning Trial in Wuhan, Nanchang (Prediction of glioma grading and molecular subtype)
Recruiting
- Glioma (Diagnosis)
- +2 more
- Prediction of glioma grading and molecular subtype
-
Wuhan, Hubei, China
- +1 more
Sep 8, 2022
Treatment Outcomes in Freeman-Sheldon Syndrome
Recruiting
- Freeman-Burian Syndrome
- +7 more
- Guided Health History for Freeman-Burian Syndrome Questionnaire
- +9 more
-
Fairfax, VirginiaOffice of Craig R Dufresne, MD, PC
Jul 15, 2022
NSCLC (NSCLC) Trial in Japan, United States (Patritumab deruxtecan, Osimertinib)
Recruiting
- Non-Small Cell Lung Cancer (NSCLC)
- Patritumab deruxtecan
- Osimertinib
-
Santa Monica, California
- +13 more
Feb 1, 2023
Non-Invasive Chromosomal Evaluation of 22q11.2
Completed
- 22q.11.2 Deletion/Duplication
-
Brussles, BelgiumThe Fetal Medicine Foundation Belgium
Apr 28, 2020
22Q11 Deletion Syndrome, tACS Trial (at-home tACS using Starstim-Home tES)
Not yet recruiting
- 22Q11 Deletion Syndrome
- tACS
- at-home tACS using Starstim-Home tES
- (no location specified)
Dec 15, 2022
Myelodysplastic Syndrome Trial in France, Germany, Spain (Lenalidomide, Placebo)
Active, not recruiting
- Myelodysplastic Syndrome
- Lenalidomide
- Placebo
-
Strasbourg, Bajo Rin, France
- +24 more
Nov 22, 2021
Acute Biphenotypic Leukemia, Acute Erythroid Leukemia in Remission, Acute Leukemia in Remission Trial in Seattle (drug,
Terminated
- Acute Biphenotypic Leukemia
- +29 more
- Cyclophosphamide
- +7 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Jan 4, 2023
Examining Genetic Factors That Affect Severity of 22q11.2
Recruiting
- DiGeorge Syndrome
- 22q11.2 Deletion Syndrome
-
New York, New York
- +1 more
Jul 18, 2022
Analyze Occurrence of Transformation From Myelodysplastic
Completed
- Myelodysplastic Syndromes
- Leukemia, Myeloid, Acute
-
Kobe, Hyogo, JapanShinko Hospital
Jun 13, 2022
Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission, Adult Acute Myeloid Leukemia in
Active, not recruiting
- Accelerated Phase Chronic Myelogenous Leukemia
- +125 more
- tetanus-CMV fusion peptide vaccine
- laboratory biomarker analysis
-
Duarte, CaliforniaCity of Hope Medical Center
Feb 28, 2022
Haploinsufficiency of RBM22 and SLU7 Genes in Del(5q)
Recruiting
- Myelodysplastic Syndromes
- +2 more
- somatic cytogenetic and genetic characterization
-
Brest, France
- +2 more
Jan 6, 2021
(Williams Syndrome Skin and Vessel Elasticity Study)
Completed
- Williams Syndrome
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 19, 2023
Healthy Trial in Philadelphia (Blood draw)
Active, not recruiting
- Healthy
- Blood draw
-
Philadelphia, PennsylvaniaThe Clinical Translational Research Center (CTRC) at the Hospita
Aug 16, 2022
Chromosome 18 Clinical Research Center
Recruiting
- Chromosome Aberrations
- +2 more
- Determination of growth hormone status
- +12 more
-
San Antonio, Texas
- +1 more
Nov 1, 2022